|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
26.31(B) |
Last
Volume: |
3,294,635 |
Avg
Vol: |
2,072,018 |
52
Week Range: |
$64 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 520 |
Guru Rank Value : 3.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
4,915 |
71,783 |
301,616 |
583,537 |
Total Sell Value |
$371,314 |
$9,377,154 |
$39,059,786 |
$70,857,495 |
Total People Sold |
5 |
8 |
14 |
16 |
Total Sell Transactions |
7 |
19 |
46 |
88 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
|
2022-09-08 |
4 |
A |
$0.00 |
$4 |
D/D |
4,051 |
49,942 |
|
- |
|
Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
|
2022-09-01 |
4 |
AS |
$81.63 |
$408 |
D/D |
(5) |
26,536 |
|
31% |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2022-08-23 |
4 |
AS |
$84.21 |
$84,210 |
D/D |
(1,000) |
137,700 |
|
37% |
|
Dahut Karen M |
Director |
|
2022-08-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,548 |
6,768 |
|
- |
|
Dahut Karen M |
Director |
|
2022-08-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,548 |
5,492 |
|
- |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2022-07-25 |
4 |
AS |
$83.07 |
$83,070 |
D/D |
(1,000) |
138,700 |
|
41% |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2022-06-23 |
4 |
AS |
$72.55 |
$72,550 |
D/D |
(1,000) |
139,700 |
|
- |
|
Sylvain Jereme M |
EVP Chief Financial Officer |
|
2022-06-06 |
4 |
AS |
$301.57 |
$180,942 |
D/D |
(600) |
17,408 |
|
- |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2022-05-24 |
4 |
AS |
$296.33 |
$74,083 |
D/D |
(250) |
35,175 |
|
- |
|
Foletta Mark G |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
1,122 |
1,122 |
|
- |
|
Skyler Jay S |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
969 |
969 |
|
- |
|
Dahut Karen M |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
987 |
1,760 |
|
- |
|
Topol Eric |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
988 |
988 |
|
- |
|
Augustinos Nicholas |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
994 |
994 |
|
- |
|
Altman Steven R |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
979 |
979 |
|
- |
|
Malady Kyle |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
979 |
3,161 |
|
- |
|
Kahn Barbara |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
994 |
994 |
|
- |
|
Collins Richard Alexander |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
987 |
987 |
|
- |
|
Heller Bridgette P |
Director |
|
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
988 |
5,355 |
|
- |
|
Foletta Mark G |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,054 |
13,651 |
|
- |
|
Foletta Mark G |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,054) |
0 |
|
- |
|
Skyler Jay S |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
900 |
14,868 |
|
- |
|
Skyler Jay S |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(900) |
0 |
|
- |
|
Dahut Karen M |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
918 |
1,305 |
|
- |
|
Dahut Karen M |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(918) |
773 |
|
- |
|
1713 Records found
|
|
Page 7 of 69 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|